Moderna Inc [NASDAQ: MRNA] closed the trading session at $53.29.
The stocks have a year to date performance of -46.42 percent and weekly performance of -3.50 percent. The stock has been moved at -55.98 percent over the last six months. The stock has performed -9.25 percent around the most recent 30 days and changed -34.65 percent over the most recent 3-months.
If compared to the average trading volume of 4.84M shares, MRNA reached to a volume of 5748321 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Moderna Inc [MRNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $90.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.63. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Bernstein have made an estimate for Moderna Inc shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on October 17, 2024. The new note on the price target was released on September 13, 2024, representing the official price target for Moderna Inc stock. Previously, the target price had yet another drop from $88 to $70, while JP Morgan kept a Underweight rating on MRNA stock. On September 13, 2024, analysts decreased their price target for MRNA shares from 120 to 65.
The Average True Range (ATR) for Moderna Inc is set at 2.27, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 4.06. The Price to Book ratio for the last quarter was 1.75, with the Price to Cash per share for the same quarter was set at 22.08.
MRNA stock trade performance evaluation
Moderna Inc [MRNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.50. With this latest performance, MRNA shares dropped by -9.25% in over the last four-week period, additionally sinking by -55.98% over the last 6 months – not to mention a drop of -31.27% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 30.23, with the RSI for the last a single of trading hit 31.28, and the three-weeks RSI is set at 30.10 for Moderna Inc [MRNA]. The present Moving Average for the last 50 days of trading for this stock 63.57, while it was recorded at 54.11 for the last single week of trading, and 99.88 for the last 200 days.
Moderna Inc [MRNA]: An insightful look at the core fundamentals
Moderna Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.92 and a Current Ratio set at 4.09.
Moderna Inc [MRNA]: Institutional Ownership
There are presently around $72.14%, or 79.73%% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 43.45 million shares, which is approximately 11.3741%. VANGUARD GROUP INC, holding 39.56 million shares of the stock with an approximate value of $$4.7 billion in MRNA stocks shares; and VANGUARD GROUP INC, currently with $$3.04 billion in MRNA stock with ownership which is approximately 6.6917%.
